Maze Therapeutics has presented glycogen [starch] synthase, muscle (GYS1) inhibitors reported to be useful for the treatment of cancer and Pompe disease.
Gilead Sciences Inc. has patented glucagon-like peptide 1 (GLP-1) receptor agonists reported to be useful for the treatment of type 2 diabetes, obesity, prediabetes, atherosclerosis, metabolic syndrome, stroke, nonalcoholic steatohepatitis and renal disorders, among other disorders.
Hereditary tyrosinemia type 1 (HT1) is an inborn error of metabolism caused by deficiency of the fumarylacetoacetate hydrolase (FAH) enzyme and people with it are unable to metabolize the amino acid tyrosine. Toxic metabolites accumulate in the liver leading to severe oxidative damage.
Eli Lilly & Co. has synthesized macrocyclic peptides acting as amylin receptor agonists, glucose- and/or triglyceride-lowering agents reported to be useful for the treatment of type 2 diabetes, obesity, dyslipidemia and nonalcoholic steatohepatitis.
Researchers from the University of Coimbra presented data from a study that aimed to assess the role of the ghrelin/neuropeptide Y (NPY) system in adipose tissue in subjects with obesity and metabolic syndrome.
Cell death induced by hypoxia is quite a common problem during pancreatic islet transplantation and is caused by insufficient revascularization of the grafts. It has been reported that the loss of NLR family pyrin domain containing 3 (NLRP3) in pancreatic islet cells protects them from hypoxia-induced cell death, so it was hypothesized that blockade of NLRP3 would improve pancreatic islet transplantation.
Researchers from the University of Zurich presented data from a study that aimed to investigate the impact of liver-specific apoptosis signal regulating kinase 1 (ASK1) overexpression on the development of high-fat diet (HFD)-induced obesity and impaired glucose metabolism.
Deciduous Therapeutics Inc. has disclosed compounds with the ability to activate invariant natural killer T cells (iNKT) and that are reported to be useful for the treatment of obesity.
RSS
